Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer - read this article along with other careers information, tips and advice on BioSpace
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
April 15, 2021 02:00 ET | Source: Sitryx Therapeutics Sitryx Therapeutics LONDON, UNITED KINGDOM
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of Iain Kilty, Ph.D., as its Chief Scientific Officer.
Iain will lead the development and execution of the Company’s research strategy and advancement of the Company’s pipeline of disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
A New Frontier to Fight This Hair-Loss Disease
Copy link
Caption
Alopecia areata, an autoimmune disease in which patients lose hair in random patches, impacts 2 percent of people globally, yet there are no FDA-approved treatments. But promising options are emerging.
By Ian Graber-Stiehl
Copy link
WHY YOU SHOULD CARE
Because this disease affects 2 percent of people globally and might be on the verge of its first effective treatment.
By Ian Graber-Stiehl
Alopecia areata, an autoimmune disease in which patients lose hair in random patches, impacts 2 percent of people globally, yet there are no FDA-approved treatments. People with the condition are also more prone to depression.